Kesatuan Eropah - Romania - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - produsele imunologice pentru leporide - iepuri - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenți antineoplazici - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. pentru informații suplimentare cu privire la starea receptorului factorului de creștere epidermal uman 2 (her2), vă rugăm să consultați secțiunea 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. pentru informații suplimentare cu privire la starea her2, vă rugăm să consultați secțiunea 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Kesatuan Eropah - Romania - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - antitrombina alfa - deficitul de antitrombină iii - agenți antitrombotici - atryn este indicat pentru profilaxia tromboembolismului venos în chirurgie de pacienți cu deficiență congenitală de antitrombină. atryn este în mod normal administrat în asociere cu heparină sau heparină cu greutate moleculară mică.

Romania - Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

roche pharma ag - germania - interferonum alfa 2a - sol. inj. - 9milioaneui/0,5ml - imunostimulante interferoni

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glaxosmithkline biologicals s.a. - vaccin papilomavirus uman (tipurile 16 dacă 18) - suspensie injectabila - 1 doza

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novo nordisk a/s - insulinum umane - soluţie injectabilă - 100 ui/ml

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - corifollitropinum alfa - solutie injectabila in seringa preumpluta - 100 mcg/0,5 ml

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - corifollitropinum alfa - solutie injectabila in seringa preumpluta - 150 mcg/0,5 ml

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lilly france s.a.s. - insulinum lispro - solutie injectabila in cartus - 100 ui/ml

Moldova - Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

eli lilly and company - insulinum umane - suspensie injectabila - 100 ui/ml